148 related articles for article (PubMed ID: 36462252)
1. [Prostate cancer screening with Prostate-Specific Antigen (PSA) to men over 70 years old in an urban health zone, 2018-2020: A cross-sectional study].
Urquijo-Moraza A; Guinea-Castañares J; Iturralde-Iriso JM
Semergen; 2023; 49(1):101876. PubMed ID: 36462252
[TBL] [Abstract][Full Text] [Related]
2. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
[TBL] [Abstract][Full Text] [Related]
3. [Use of prostatic specific antigen in primary care (PSA)].
Panach-Navarrete J; Gironés-Montagud A; Sánchez-Cano E; Doménech-Pérez C; Martínez-Jabaloyas JM
Semergen; 2017 Apr; 43(3):189-195. PubMed ID: 27344583
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer early detection among primary care physicians in Mexico: A cross-sectional study.
Basulto-Martínez M; Ojeda-Pérez JE; Velueta-Martínez IA; Cueto-Vega GJ; Flores-Tapia JP; González-Losa MDR
Cir Cir; 2021; 89(2):163-169. PubMed ID: 33784274
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
6. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
Mori RR; Faria EF; Mauad EC; Rodrigues AA; Dos Reis RB
Int Braz J Urol; 2020; 46(1):34-41. PubMed ID: 31851456
[TBL] [Abstract][Full Text] [Related]
8. Mass screening of prostate cancer in Changchun City of China.
Li X; Tsuji I; Kuwahara M; Zhang H; Wang H; Zhang L; Ji G; Zhao X
Int Urol Nephrol; 2004; 36(4):541-8. PubMed ID: 15787333
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
10. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
12. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
[TBL] [Abstract][Full Text] [Related]
13. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
14. Recurrence rate of localized prostate cancer after radical prostatectomy according to D'amico risk classification in a tertiary referral hospital: association study.
Valdez-Vargas AD; Sánchez-López HM; Badillo-Santoyo MA; Maldonado-Valadez RE; Manzo-Pérez BO; Pérez-Abarca VM; Manzo-Pérez G; Vanzzini-Guerrero MA; Álvarez-Canales JA
Cir Cir; 2021; 89(4):520-527. PubMed ID: 34352860
[TBL] [Abstract][Full Text] [Related]
15. Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018.
Richards TB; Dai S; Gray SC; Hall IJ; Siegel DA
Urol Oncol; 2022 May; 40(5):192.e19-192.e25. PubMed ID: 35236620
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C
BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132
[TBL] [Abstract][Full Text] [Related]
17. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
18. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
